Is Questcor Pharmaceuticals Inc (QCOR) Going to Burn These Hedge Funds?
In today’s marketplace, there are a multitude of methods shareholders can use to watch stocks.
Posts Tagged ‘NASDAQ:ARNA’
The Amgen, Inc. (AMGN)-Onyx Pharmaceuticals, Inc. (ONXX) Deal Should Make All Biotech Investors Happy
While that's certainly not what Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) investors were hoping for -- at one point, after Amgen, Inc.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA), Orexigen Therapeutics, Inc. (OREX): Who Will Be the Winner in the Fight Against Obesity?
The obesity segment of the health care industry is turning into a battleground. VIVUS, Inc.
Pharma News: Vivus, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA)’s Settled Stock & Amgen, Inc. (AMGN)’s Clinical Trial
Investors in Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) saw new options become available this week, for the April 2014 expiration. ...VIVUS, Inc.
Hedge Funds Are Selling Arena Pharmaceuticals, Inc. (ARNA)
Now, according to many market players, hedge funds are viewed as delayed, outdated financial tools of an era lost to time.
Alnylam Pharmaceuticals, Inc. (ALNY): Insiders Aren’t Crazy About It But Hedge Funds Love It
If you were to ask many market players, hedge funds are seen as useless, outdated financial tools of a period lost to current times.
Pharma News: VIVUS, Inc. (VVUS)’s Injury, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Agreement
The ratings of four Pharmaceutical stocks are down this week, according to the Portfolio Grader database.
MannKind Corporation (MNKD), Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS) – Attention Biotech Investors: Stop Looking at Share Price
After my article on MannKind Corporation (NASDAQ:MNKD) earlier this week, a reader wasn't too happy about my view that the company was overvalued given the most recent phase ...
Merck & Co., Inc. (MRK), Pfizer Inc. (PFE): Alarming New Obesity Data Points to a Scary Trend
Last week, the Trust for America's Health and the Robert Wood Johnson Foundation released their annual report (link opens a PDF to a 116-page report) on obesity trends in the ...
McDonald’s Corporation (MCD), Chipotle Mexican Grill, Inc. (CMG), Yum! Brands, Inc. (YUM): This Disturbing New Fast-Food Data Points to a Scary Trend
We are a nation that is completely and utterly devoted to the convenience of fast food.
Pharma News: VIVUS, Inc. (VVUS) Qsymia Patents, Arena Pharmaceuticals, Inc. (ARNA) Earnings, Amgen, Inc. (AMGN) Ending an Agreement
Earlier today RFD IP Business Services ("RFD") released a new report analyzing the likely inequitable conduct challenges to VIVUS, Inc.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Can the Newly Discovered Obesity Genes Help You Lose Weight?
Quite a few research papers published recently have shown that mutations in genes can control your appetite and your ability to burn calories.
McDonald’s Corporation (MCD), Chipotle Mexican Grill, Inc. (CMG): This Disturbing New Fast-Food Data Points to a Scary Trend
We are a nation that is completely and utterly devoted to the convenience of fast food.
CYS Investments Inc (CYS), American International Group Inc (AIG), Staples, Inc. (SPLS): Here’s What These Quantitative Investors Have Been Buying
Today, let's look at Analytic Investors, founded in 1970 and based far from Wall Street, in Los Angeles.
Arena Pharmaceuticals, Inc. (ARNA): What Do The Smartest Investors Think?
In the financial world, there are tons of indicators investors can use to watch their holdings. Some of the most under-the-radar are hedge fund and insider trading sentiment.
Alnylam Pharmaceuticals, Inc. (ALNY): Here’s What The Smart Money Thinks
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) the right investment to pursue these days? Hedge funds are taking a bullish view.
WellPoint, Inc. (WLP), Arena Pharmaceuticals, Inc. (ARNA): Does This Data Overwhelmingly Prove That We Need Obamacare?
Regardless of whether you're entirely for the Patient Protection and Affordable Care Act, vehemently against it, or fall somewhere in between, it's set to become the law of the...
Arena Pharmaceuticals, Inc. (ARNA): Nothing to See Here, No Huge Sales Yet
The sales come from less than a month on the market -- the drug launched on June 11 and the quarter closed on June 30 -- and can't tell you anything about the long-term potential...
Will Arena Pharmaceuticals, Inc. (ARNA) Earnings Finally Explode Higher?
Arena Pharmaceuticals, Inc.
Pharma News: Vivus, Inc. (VVUS)’s New CEO, Arena Pharmaceuticals, Inc. (ARNA) & Amgen, Inc. (AMGN)’s Positive Earnings
VIVUS, Inc. (NASDAQ:VVUS), which sells the obesity drug Qsymia, has appointed Anthony Zook to serve as its CEO.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): How You Should Play These Weight-Loss Drug Companies
The two weight-loss drug approvals in 2012 were the first in more than a decade. The excitement surrounding Arena Pharmaceuticals, Inc.
VIVUS, Inc. (VVUS), AstraZeneca plc (ADR) (AZN): Great Job, Now You’re Fired
"As a founding CEO, over the past 22 years, Leland has secured four drug approvals, an unheard-of achievement for a small pharmaceutical company. He has taken VIVUS, Inc.
What Should You Expect From Arena Pharmaceuticals, Inc. (ARNA) and VIVUS, Inc. (VVUS)?
For a long time, VIVUS, Inc. (NASDAQ:VVUS) was operating as the only player in the anti-obesity market. However, the entry by Arena Pharmaceuticals, Inc.
VIVUS, Inc. (VVUS), Merck & Co., Inc. (MRK): What’s Your Biggest Fear? The Answer Might Scare You!
With all of the factors we have to worry about in our everyday lives, it is somewhat a wonder that we're not only able to survive, but thrive, as a society.
Eli Lilly & Co. (LLY), Teva Pharmaceutical Industries Ltd (ADR) (TEVA): The 3 Most Commonly Diagnosed Mental Disorders
The medical community certainly spends a lot of time and money researching treatments for cardiovascular disease and cancer.
Arena Pharmaceuticals, Inc. (ARNA): 1 Biotech You Might Want to Explore Right Now!
After more than a year, Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’ weight-loss drug Belviq has finally launched.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): One Weight-Loss Drug That Investors Forgot
You know Belviq and Qsymia and Contrave and Empatic, but do you recall the still most widely used weight-loss drug of all? It seems almost like ancient history now, but back in...
VIVUS, Inc. (VVUS): Obesity Drug Finally Hits Pharmacies
After gaining Food and Drug Administration approval nearly a year ago, patients can finally walk into a pharmacy and get their prescription for VIVUS, Inc.
Elan Corporation, plc (ADR) (ELN), VIVUS, Inc. (VVUS), MannKind Corporation (MNKD): Three Biotech Companies to Watch This Summer
The news flow from biotech companies might slow down during the summer, but it won't stop.
Arena Pharmaceuticals, Inc. (ARNA), VIVUS, Inc. (VVUS): Payday on the Way for America’s New Epidemic Disease?
If that word is "disease," it could be billions of dollars. The American Medical Association, or AMA, recently decided to categorize obesity as a disease.
VIVUS, Inc. (VVUS), ISIS Pharmaceuticals, Inc. (ISIS), Gilead Sciences, Inc. (GILD): Biotech Companies Battle It Out
Biotech companies sometimes get lucky, launching a drug into a new indication where there's no competition, but more often than not the biotech companies have to battle it out...
VIVUS, Inc. (VVUS): Qsymia Just Won The Lotto
After almost a decade, the FDA has once again started approving obesity drugs. VIVUS, Inc. (NASDAQ:VVUS)’s Qysmia and Arena Pharmaceuticals, Inc.
Pharma News: VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA) & ACADIA Pharmaceuticals Inc. (ACAD)
Editor's Note: Related tickers: VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), ACADIA Pharmaceuticals Inc.
VIVUS, Inc. (VVUS): An Obese Proxy Fight
Proxy fights are like the demolition derby of the investment world.
Ariad Pharmaceuticals, Inc. (ARIA), VIVUS, Inc. (VVUS): Winning Biotech Investment Strategies and Their Potential Pitfalls
Investing in biotech companies isn't without its challenges, but it doesn't have to be a shot in the dark, either.
Aegerion Pharmaceuticals, Inc. (AEGR), Arena Pharmaceuticals, Inc. (ARNA): Investment Opportunities in Drug Launches
There are investment opportunities in every sector, but biotechs launching new drugs offer a unique investment opportunity to take advantage of hyper-growth as sales increase ...
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Weight Loss Drug Sweepstakes
First investors were reminded of the struggle between VIVUS, Inc. (NASDAQ:VVUS), Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Orexigen Therapeutics, Inc.
Why I’m Buying Weight Watchers International, Inc. (WTW)
A historic view of recurring themes in major wartime conflicts, our puzzling tendency to continuously overeat, and the pie-in-the-sky popularity of Charles Duhigg's The Power ...
Arena Pharmaceuticals, Inc. (ARNA): The Short Data You Need To See
Nowadays, there are a multitude of indicators for Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) traders to pay attention to, but it's smart to take note of a stock's shorts.
What to Expect From Arena Pharmaceuticals, Inc. (ARNA)’s Launch of Belviq
After years of anticipation by doctors, patients, and investors, Belviq was finally launched last week for treatment of obesity, type 2 diabetes and overweight patients with a...
Arena Pharmaceuticals, Inc. (ARNA) News: Positive Rating, Anti-Obesity Drug, Post-Launch Presentation & More
Editor's Note: Related tickers: Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), VIVUS, Inc. (NASDAQ:VVUS), Orexigen Therapeutics, Inc.
Abbott Laboratories (ABT), VIVUS, Inc. (VVUS) – It’s Official: Obesity Is a Disease
The decision wasn't without debate, though. In fact, the AMA's Council on Science and Public Health actually recommended against calling obesity a disease.
MannKind Corporation (MNKD), Orexigen Therapeutics, Inc. (OREX): Two Biotech Approval Outcomes That Might Affect You
An FDA approval is the Holy Grail for biotechnology companies and their investors – but a successful launch is the most momentous in producing long-term gains.
VIVUS, Inc. (VVUS), Arena Pharmaceuticals, Inc. (ARNA): Consumer Reports Says “Exercise” Rather Than Take This Drug
The U.S. weight loss market is estimated at $61 billion, with the global weight management market expected to be $650 billion by 2015.
Onyx Pharmaceuticals, Inc. (ONXX), Arena Pharmaceuticals, Inc. (ARNA): The Top 5 Diseases Caused by Obesity
In the "Global Burden of Disease" report from the World Health Organization, which was compiled over a 20-year period from 1990 through 2010 using data from 500 researchers from...
Arena Pharmaceuticals, Inc. (ARNA): An Obesity Drug Stock to Fatten your Portfolio?
Arena Pharmaceuticals, Inc.
Arena Pharmaceuticals, Inc. (ARNA), Rigel Pharmaceuticals, Inc. (RIGL): This Week in Biotech
With the SPDR S&P Biotech Index up 38% over the trailing-12-month period, it's evident that investment dollars are willingly flowing into the biotech sector.
